Integrin alpha V (ITGAV) expression in esophageal adenocarcinoma is associated with shortened overall-survival

Heike Loeser2,4,5, Matthias Scholz1,4,5, Hans Fuchs3,4, Ahlem Essakly3,4, Alexander Iannos Damanakis1,4, Thomas Zander3,4, Reinhard Büttner2,4, Wolfgang Schröder1,4, Christiane Bruns1,4, Alexander Quaas2,4,5 & Florian Gebauer1,4,5

Valid biomarkers for a better prognostic prediction of the clinical course in esophageal adenocarcinoma (EAC) are still not implemented. Integrin alpha V (ITGAV), a transmembrane glycoprotein responsible for cell-to-matrix binding has been found to enhance tumor progression in several tumor entities. The expression pattern and biological role of ITGAV expression in esophageal adenocarcinoma (EAC) has not been analyzed so far. Aim of the study is to evaluate the expression level of ITGAV in a very large collective of EAC and its impact on individual patients’ prognosis. 585 patients with esophageal adenocarcinoma were analyzed immunohistochemically for ITGAV. The data was correlated with clinical, pathological and molecular data (TP53, HER2/neu, c-myc, GATA6, PIK3CA and KRAS). A total of 85 patients (14.3%) out of 585 analyzable tumors showed an ITGAV expression and intratumoral heterogeneity was low. ITGAV expression was correlated with a shortened overall-survival in the patients’ group that underwent primary surgery (p = 0.014) but not in the group of patients that received neoadjuvant treatment before surgery. No correlation between any of the analyzed molecular marker (mutations or amplifications) (TP53, HER2, c-myc, GATA6, PIK3CA and KRAS) and ITGAV expression could be observed. A multivariate cox-regression model was performed which showed tumor stage, lymph node metastasis and ITGAV expression as independent prognostic markers for overall-survival in the group of patients without neoadjuvant treatment. ITGAV expression is correlated with an impaired patient outcome in the group of patients without neoadjuvant therapy and serves as a prognostic factor in EAC.

Esophageal cancer is the eighth most common cancer and sixth leading cause of cancer death in the world1. While advantages in perioperative treatment have been achieved including establishment of standardized perioperative treatment protocols and surgical procedures with acceptable low perioperative morbidity and mortality rates, the overall-survival of patients with esophageal adenocarcinoma (EAC) remains limited2. Today, treatment response prediction or even stratification into high- and low-risk tumors is hardly possible or only done by clinical parameter. Therefore, the identification of individual prognostic markers is of high importance, as there is a high fraction of patients receiving multimodal treatment with only limited or even without any histopathological response and therefore limited individual benefit considering long-term survival3.

Integrins are a family of cell-adhesion molecules that consist of two linked heterodimeric subunits, the α and β subunit and mediate cell–cell and cell-to-extracellular matrix (ECM) adhesions4. The combination of the particular α and β subunit determines the receptor specificity, however, integrins are physiologically involved in promoting signaling pathways that regulate proliferation, cell survival, and migration5. Integrins have become of interest in cancer research as there are distinct roles of certain Integrin α/β combinations in carcinogenesis and tumor progression, with focus on metastatic processes and interactions between tumor cells and the ECM6.

1Department of General, Visceral, Cancer and Transplantation Surgery, University of Cologne, Kerpener Strasse 62, 50937 Cologne, Germany. 2Institute of Pathology, University of Cologne, Cologne, Germany. 3Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, Cologne, Germany. 4Gastrointestinal Cancer Group Cologne GCGC, University of Cologne, Cologne, Germany. These authors contributed equally: Heike Loeser, Matthias Scholz, Alexander Quaas, and Florian Gebauer. *email: florian.gebauer@uk-koeln.de
Integrin αV (ITGAV) consists of five members αvβ1, αvβ3, αvβ5, αvβ6 and αvβ8 and is part of the receptors for fibronectin, vitronectin, fibrinogen. It was previously found overexpressed in different tumor types and partly associated with shortened overall-survival (OS)7–10. However, the expression pattern and biological role of ITGAV expression in esophageal adenocarcinoma (EAC) has not been analysed so far. Furthermore, as integrins are important in cancer progression, a systematic analysis of ITGAV expression and known molecular alterations in EAC was performed. The aim of the present study is therefore to analyze the expression of ITGAV in a collective of almost 700 patients with EAC and correlate the expression profile to clinicopathological, molecular (TP53, Her2/neu, c-myc, GATA6, PIK3CA and KRAS amplification) and survival data.

Patients and methods

Patients and tumor samples. Formalin-fixed and paraffin embedded tumor tissue of 685 patients with esophageal adenocarcinomas that underwent primary surgical resection or resection after neoadjuvant therapy at the Department of General, Visceral and Cancer Surgery, University of Cologne, Germany was analyzed as previously described11,12. The standard surgical procedure consisted of a transthoracic en-bloc esophagectomy with two-field lymphadenectomy (abdominal and mediastinal lymph nodes), reconstruction by formation of a gastric tube with intrathoracic esophagogastrostomy (Ivor-Lewis esophagectomy)13. The abdominal phase was predominantly performed as a laparoscopic procedure (hybrid Ivor-Lewis esophagectomy). Technical details of this operation are described elsewhere14–16. Patients with locally advanced esophageal cancer (cT3) or evidence for loco regional lymph node metastasis in clinical staging received preoperative chemoradiation (5-Fluoracil, cisplatin, 40 Gy) or chemotherapy alone. Follow-up data were available for all patients (Table 1).

Single spot tissue micro arrays (TMA) were built for immunohistochemical analyses. TMA construction was performed as previously described11,12,17. In brief, tissue cylinders with a diameter of 1.2 mm each were punched from selected tumor tissue blocks using a self-constructed semi-automated precision instrument and embedded in empty recipient paraffin blocks. For the multi-spot TMA (165 patients), up to eight tumor spots were punched out of the tumour, four spots each from the surface and the invasion front. The multi-spot array should answer the question of heterogeneity of an ITGAV expression within the tumor. Four μm sections of the resulting TMA blocks were transferred to an adhesive coated slide system (Instrumedics Inc., Hackensack, NJ) for immunohistochemistry. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The present study was ethically approved by the University of Cologne Ethics Committee (reference no. 13-091) and written informed consent was obtained from all patients.

Immunohistochemistry for Integrin alpha V (ITGAV). Immunohistochemistry (IHC) was performed on TMA slides using the Integrin alpha V rabbit monoclonal antibody (ab150361; dilution 1:300; Abcam, UK). Staining and scoring procedures were conducted as previously described12,18–20. All immunohistochemical stainings were performed using the Leica BOND-MAX stainer (Leica Biosystems, Germany) according to the protocol of the manufacturer. The membraneous staining pattern was scored manually and independently by two pathologists (A.Q. and H.L.) according to a 4-tier-scoring system. Score 3+ was defined as a strong staining of ≥30% of tumor cells or moderate staining ≥70%. A weak staining in >70% or moderate staining in >30 and ≤70% or as strong staining in ≤30% of tumor cells was considered as Score 2+. Score 1+ was assigned when ≤70% of tumor cells were weakly positive or ≤30% were moderately stained. Less staining was defined as negative (Score 0). Discrepant results were resolved by consensus review.

Expression of Integrin alpha V was correlated with molecular markers including analysis of TP53, Her2/neu, c-myc, GATA6, PIK3CA- and KRAS amplification. A detailed description of the analysis of TP53, KRAS, PIK3CA, Her2/neu and GATA6 is already published11,12,19,21.

Statistical analysis. Clinical data were collected prospectively and analyzed according to a standardized protocol as previously described11,12. SPSS Statistics for Mac (Version 21, SPSS) was used for statistical analysis. Interdependence between stainings and clinical data were calculated using the chi-squared and Fisher's exact tests, and displayed by cross-tables. Survival curves were plotted using the Kaplan–Meier method and analyzed using the log-rank test. All tests were two-sided. P values < 0.05 were considered statistically significant.

Results

Patients’ baseline characteristics. On the TMA a total of 585 patients of 685 (86.7%) were immunohistochemically interpretable for ITGAV. Reasons for the non-informative cases were missing tissue samples or the absence of distinct cancer tissue in the TMA spot. Clinicopathological data is depicted in Table 1. Patients were predominantly men (male n = 520, 87.4%; female n = 75, 12.6%). The median age of the entire patient cohort at the time of diagnosis was 65.2 years (range 33.6–85.6 years). In 333 patients (56.0%) a neoadjuvant treatment (chemo- or radiochemotherapy) was performed before surgery.

Expression of ITGAV in esophageal adenocarcinoma. Expression of ITGAV was detectable in 85 patients (14.3%) (Fig. 1). In cross table analysis a correlation between ITGAV expression, older patients (>65 years) and advanced tumor staged could be revealed (p = 0.05 and p = 0.005, respectively). No correlation between any of the analyzed molecular marker (TP53 mutation, HER2/neu, c-myc, GATA6, PIK3CA and KRAS amplifications) and ITGAV expression was seen (Table 2).

To analyze heterogeneity of ITGAV expression within the tumor we performed an analysis of 165 patients on our multi-spot TMA. A homogeneous distribution of ITGAV expression within the tumors was observed.
|                                | Total | Integran αV expression |   |   | p value |
|--------------------------------|-------|------------------------|--|--|--
| **Sex**                        |       |                        |   |   |        |
| Female                         | 75    | 61                     | 14 |   |        |
|                               | % 12.6 | 81.3%                 | 18.7% | |        |
| Male                           | 520   | 449                    | 71  |   |        |
|                               | % 87.4 | 86.3%                 | 13.7%  | 0.288|
| **Age group**                  |       |                        |   |   |        |
| <65 years                      | 309   | 256                    | 53  |   |        |
|                               | % 51.9 | 83.0%                 | 17.0%  | |        |
| >65 years                      | 286   | 254                    | 32  |   |        |
|                               | % 48.1 | 88.6%                 | 11.4%  | 0.056|
| **Tumor stage**                |       |                        |   |   |        |
| pT1                            | 86    | 75                     | 11  |   |        |
|                               | % 14.5 | 87.2%                 | 12.8%  | |        |
| pT2                            | 74    | 68                     | 6   |   |        |
|                               | % 12.5 | 91.9%                 | 8.1%   | |        |
| pT3                            | 411   | 351                    | 60  |   |        |
|                               | % 69.4 | 85.4%                 | 14.6%  | |        |
| pT4                            | 19    | 11                     | 8   |   |        |
|                               | % 3.2  | 57.9%                 | 42.1%  | 0.005|
| **Lymph node metastasis**      |       |                        |   |   |        |
| pN0                            | 238   | 210                    | 28  |   |        |
|                               | % 40.3 | 88.2%                 | 11.8%  | |        |
| pN+                            | 352   | 296                    | 56  |   |        |
|                               | % 59.7 | 84.1%                 | 15.9%  | 0.187|
| **UICC**                       |       |                        |   |   |        |
| I                              | 121   | 106                    | 15  |   |        |
|                               | % 20.6 | 87.6%                 | 12.4%  | |        |
| II                             | 142   | 127                    | 15  |   |        |
|                               | % 24.1 | 89.4%                 | 10.6%  | |        |
| III                            | 251   | 207                    | 44  |   |        |
|                               | % 42.7 | 82.5%                 | 17.5%  | |        |
| IV                             | 74    | 64                     | 10  |   |        |
|                               | % 12.3 | 86.5%                 | 13.5%  | 0.245|
| **Neoadjuvant treatment**      |       |                        |   |   |        |
| No                             | 262   | 228                    | 34  |   |        |
|                               | % 44.0 | 87.0%                 | 13.0%  | |        |
| Yes                            | 333   | 282                    | 51  |   |        |
|                               | % 56.0 | 84.7%                 | 15.3%  | 0.479|

**Table 1.** Clinico-pathological data of the entire patients cohort and cross-table analysis of Integrin alphaV expression.
The total frequency of ITGAV expression on the multi-spot TMA was lower than on the single spot TMA. Eight of 165 patients were positive for ITGAV on at least 2 spots (4.8%), two of these patients showed no evidence of ITGAV expression at the infiltration zone. There was a strong correlation between positive and negative patients on the single-spot and multi-spot TMA (p < 0.0001).

ITGAV expression marks poor outcome in patients without neoadjuvant treatment. Observing the entire patient cohort, a significant difference between patients with and without ITGAV expression could not be observed (Fig. 2A). However, in subgroup analysis, the group of patients that did not undergo neoadjuvant treatment, ITGAV expression was associated with a shortened overall-survival (OS). Patients without expression of ITGAV showed a median OS of 41.3 months (95% confidence interval [95% CI] 18.4–64.3 months) compared to a median OS of 19.3 months (95% CI 9.4–29.2 months, p = 0.014) in the group with ITGAV positive tumors. The effect was not seen in the group of patients after neoadjuvant treatment (p = 0.757) (Fig. 2B,C). Although there was no statistically significant difference, the survival analysis showed a distinct tendency towards a shorter survival in the group of pT1/2 carcinomas depending on ITGAV expression (Fig. 3A,B). An ITGAV dependent difference in OS between patients with lymph node metastasis and those without could not be revealed (data not shown). To test whether the effects of ITGAV dependent survival differences are based on the correlation with tumor stages, a multivariate cox-regression model was performed which showed the tumor stage, lymph node metastasis and ITGAV expression as independent prognostic markers for overall-survival in the group of patients without neoadjuvant treatment (Table 3).

Discussion
EAC is one of the most aggressive gastrointestinal tumors and characterized by a high probability of metastasis as well as the occurrence of local recurrence after surgery. In the context of tumor progression, the interaction of tumor cells with the extracellular matrix is essential to ensure a tumor invasion into deeper tissue layers of the esophagus and therefore to establish a connection to the lymphatic and blood vessel system. We can show in a large patient cohort of almost 600 EAC patients that the expression of ITAGV plays a role in tumor progression.
It is associated with a poor OS in the group of patients without neoadjuvant therapy and serves as an independent prognostic marker (Fig. 4).

Integrins are natural candidates for analyzing the interaction between tumor cells and ECM because of their role as ligands for all major constitutes of the basement membrane and ECM\(^23\). The focus of this study lies in the analysis of the prognostic impact of ITGAV in the context with administration of neoadjuvant treatment in EAC patients. Under physiological circumstances, ITGAV is practically undetectable in normal tissue, however, it has been shown that ITGAV expression increases in a variety of epithelial tumors and its expression is associated with a poor prognosis\(^24\). ITGAV expression is found in about 16–18% of breast cancer\(^25,26\). Here it is remarkable that ITGAV is primarily detectable in advanced tumors, which underlines the potential role of integrin expression during tumor progression. In ovarian and pancreatic carcinoma nearly all tumors are positive for ITAGV expression, in colorectal carcinoma an expression of about 34–37% is found, in patients with synchronous liver

|               | Total  | Integrin αV expression |          |          |          |
|---------------|--------|-------------------------|----------|----------|----------|
|               |        | Negative | Negative | Negative | Total    |
| **TP53**      |        | Negative |          |          |          |
| No            | 149    | 131       | 18       |          | 149      |
| %             | 42.3%  | 87.9%     | 12.1%    |          |          |
| Positive      |        | Negative |          |          |          |
| No            | 203    | 179       | 24       |          | 203      |
| %             | 57.7%  | 88.2%     | 11.8%    |          |          |
| **HER2/neu**  |        | Negative |          |          |          |
| No            | 300    | 267       | 33       |          | 300      |
| %             | 87.7%  | 89.0%     | 11.0%    |          |          |
| Positive      |        | Negative |          |          |          |
| No            | 42     | 37        | 5        |          | 42       |
| %             | 12.3%  | 88.1%     | 11.9%    |          | 0.796    |
| **Cmyc**      |        | Wild type |          |          |          |
| No            | 407    | 353       | 54       |          | 407      |
| %             | 87.7%  | 86.7%     | 13.3%    |          |          |
| Amplified     |        | Wild type |          |          |          |
| No            | 57     | 53        | 4        |          | 57       |
| %             | 12.3%  | 93.0%     | 7.0%     |          | 0.282    |
| **GATA6**     |        | Wild type |          |          |          |
| No            | 408    | 353       | 55       |          | 408      |
| %             | 89.2%  | 86.5%     | 13.5%    |          |          |
| Amplified     |        | Wild type |          |          |          |
| No            | 47     | 42        | 5        |          | 47       |
| %             | 10.3%  | 89.4%     | 10.6%    |          | 0.819    |
| **PIK3CA**    |        | Wild type |          |          |          |
| No            | 398    | 351       | 47       |          | 398      |
| %             | 94.5%  | 88.2%     | 11.8%    |          |          |
| Amplified     |        | Wild type |          |          |          |
| No            | 23     | 18        | 5        |          | 23       |
| %             | 5.5%   | 78.3%     | 21.7%    |          | 0.184    |
| **Kras**      |        | Wild type |          |          |          |
| No            | 388    | 335       | 53       |          | 388      |
| %             | 81.5%  | 86.3%     | 13.7%    |          |          |
| Amplified     |        | Wild type |          |          |          |
| No            | 88     | 80        | 8        |          | 88       |
| %             | 18.5%  | 90.9%     | 9.1%     |          | 0.292    |

**Table 2.** Correlation between molecular data and ITGAV expression.
metastasis in up to 70% of colorectal cancer patients\textsuperscript{7,24,27,28}. So far, various mechanisms have been described to promote tumor progression by ITAGV. In particular, epithelial-mesenchymal transition (EMT), migration, cell proliferation and chemoresistance have been described as ITGAV mediated effects\textsuperscript{29}. ITGAV could be identified as EMT marker in breast, colon and pancreatic carcinoma\textsuperscript{30–32}. It was shown that the combination of integrin alpha V/beta 6 expression is closely correlated with the expression of other EMT markers, such as ZEB1 and ZEB2, and this could be explained as a possible pathway for ITAGV associated tumor cell detachment from rigid cell formation and therefore tumor progression in terms of metastatic spread\textsuperscript{24}.

**Table 3.** Multivariate cox-regression model for patients after primary surgery and neoadjuvant treatment.

|                      | Primary surgery | Neoadjuvant treatment |
|----------------------|-----------------|-----------------------|
|                      | Hazard ratio    | 95% confidence interval | p value | Hazard ratio    | 95% confidence interval | p value |
| Sex (male vs. female) | 0.74            | 0.37 1.48             | 0.394   | 1.372            | 2.361 0.254             |
| Age group (< 65yrs vs. > 65 yrs) | 1.537 | 1.011 2.339             | 0.044   | 1.319            | 1.825 0.095             |
| Tumor stage (pT1/2 vs. pT3/4) | 2.057 | 1.208 3.504             | 0.008   | 0.922            | 1.433 0.718             |
| Lymph node metastasis (pN0 vs. pN +) | 3.641 | 2.228 5.951             | < 0.001 | 2.571            | 3.732 < 0.001           |
| Integrin alphaV expression (negative vs. positive) | 2.031 | 1.102 3.741             | 0.023   | 0.951            | 1.464 0.819             |

**Figure 2.** Kaplan–Meier survival analysis (log-rank test) for the entire patients’ cohort (A), patients after primary surgery (B) and patients after neoadjuvant treatment (C).

**Figure 3.** Kaplan–Meier survival analysis (log-rank test) for patients with pT1/2 tumors (A) and pT3/4 tumors (B).
A further ITGAV mediated effect is that tumor cells with a high ITGAV expression show an increased cell migration in vivo and in vitro as well as an increased cell proliferation rate. Furthermore, the cell invasion is increased by ITGAV mediated activation of matrix metalloproteinase 9 (MMP). The above-mentioned effects could have been primarily be attributed to an ITGAV-mediated TGF-beta activation. TGF-b1 is a central mediator of tissue fibrosis and inflammation, and as an epithelial-restricted integrin, integrin αvβ6 expression is dramatically up-regulated in response to tissue injury and inflammation. ITGAV-mediated TGF-beta activation is pivotal to the progression of various diseases such as fibrotic disease of the kidney and lung, pulmonary emphysema and acute lung injury. TGF-beta-mediated tumor progression has already been demonstrated for various tumor entities. ITGAV-mediated TGF-beta activation is another activation pathway that has not been described for EAC.

Considering known molecular alterations in EAC we did not see any statistical correlation with TP53 mutation and Her2/neu, c-myc, GATA6, PIK3CA and KRAS amplification, although integrins are known to influence

**Figure 4.** Visualization of the heterogeneity of ITGAV expression within the tumor by multi-spot TMA analysis. Each line represents an individual patient, each column a spot either on the luminal tumor area or the invasive tumor area. red = ITGAV negative, blue (light to dark) = weak to strong ITGAV expression.
multiple signal pathways. For KRAS and PIK3CA, it is known that the expression of integrins can activate the RAS-MAPK-pathway and the PI3K-AKT-pathway, respectively. In tumors that show an amplification of these genes (PIK3CA, KRAS GATA6) no statistically measurable additional effect can be achieved by ITAGV expression. For TP53 and Her2/neu, for example, there are contradictory data on the prognostic significance of these markers. At least in one operable tumor collective we and others could show that Her2/neu amplification of tumors is associated with a favorable prognosis. According to the latest findings, TP53 mutations in EAC are associated with a so-called genomic catastrophe in at least part of the tumors, which is associated with chromotrypsis. This mechanism probably affects up to one third of all EACs, so that interactions of TP53 and ITAGV that have been described in other tumor entities (see below) cannot necessarily be transferred to EACs. These remarks underline once again how multifactorial molecular changes are effective. For example, in colon cancer cells, the expression of Integrinα5/β1 mediates down-regulation of Her2/neu, suggesting a tumor suppressor function of αVβ6.

It is known that mutant TP53 promotes recycling of Integrin and EGFR leading to activation of the AKT-pathway. In colon cancer cells, the activation of TP53 inhibits expression of ITAGV, leading to cell survival. We can assume that especially considering KRAS, Her2/neu, GATA6 and PIK3CA the frequency of gene alterations in EAC is low (Table 2), and thus a probable influence of ITAGV cannot be shown statistically. In this study we show that ITAGV expression is detectable in 14% of the EAC cases, which is somewhat lower than revealed in other tumor entities by TMA technique. Even though the TMA spots cover only small parts of the tumor, we have been able to show in the past that the expression in the TMA spot, especially in large number of patients, matches very well with the expression of the total tumor. We could show that there is a high concordance between the expression in the single-spot TMA for ITAGV expression and the expression on the multi-spot TMA and therefore we conclude that the TMA technique is appropriate to assess ITAGV expression pattern in esophageal adenocarcinoma. Neoadjuvant chemo-(radio)therapy concepts have no influence on the expression frequency, no significant difference in the number of positive or negative tumor samples was detectable. Interestingly, there is no ITAGV associated influence on overall survival in the overall cohort, but there is a significant survival difference in the group of patients with primary surgery. Here a clear survival disadvantage is found if ITAGV is present in the tumor cells. This effect is explainable as a driver of tumor progression, EMT and signaling as described above. This clearly identifies ITAGV as a promoter of tumor progression for EAC. Currently, we can only speculate why the survival difference is not detectable in the group of patients after neoadjuvant therapy. It is possible that neoadjuvant therapies promote fundamental structural epigenetic changes of tumor cells, so that the ITAGV mediated effects cannot be detected well by immunohistochemical analysis. Of course, due to the retrospective nature of the study the influence of perioperative therapy on ITAGV-associated effects can only be explained indirectly. Further prospective analyses are necessary, for example to investigate the significance of ITAGV expression on biopsy material. However, the effects in the group of primarily operated patients are clear and show a significantly shortened overall survival in cases with ITAGV expression, so that ITAGV may play a role as a prognostic tumor marker in the description of disease progression of EAC.

Data availability
Data available on request due to privacy/ethical restrictions.

Received: 20 May 2020; Accepted: 5 October 2020
Published online: 27 October 2020

References
1. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2019. CA Cancer J. Clin. 69(1), 7–34 (2019).
2. Shapiro, J. et al. Neoadjuvantchemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet. Oncol. 16(9), 1090–1098 (2015).
3. Al-Batran, S. E. et al. Histopathological regression after neoadjuvantdocetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capcitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol. 17(12), 1697–1708 (2016).
4. Humphries, M. J. Integrin structure. Biochem. Soc. Trans. 28(4), 311–339 (2000).
5. Lu, J. G. et al. Role of the alpha v-integrin subunit in cell proliferation, apoptosis and tumor metastasis of laryngeal and hypopharyngeal squamous cell carcinomas: a clinical and in vitro investigation. Eur. Arch. Otorhinolaryngol. 266(1), 89–96 (2009).
6. Lu, X. et al. The role of integrins in cancer and the development of anti-integrin therapeutic agents for cancer therapy. Perspect. Medicin. Chem. 2, 57–73 (2008).
7. Ha, S. Y. et al. Overexpression of integrin alphaV correlates with poor prognosis in colorectal cancer. J. Clin. Pathol. 67(7), 576–581 (2014).
8. Hecht, J. L. et al. Overexpression of the alphavbeta6 integrin in endometrial cancer. Appl. Immunohistochem. Mol. Morphol. 16(6), 543–547 (2008).
9. Wang, H. et al. Integrin subunit alpha V promotes growth, migration, and invasion of gastric cancer cells. Pathol. Res. Pract. 215(9), 152531 (2019).
10. Wu, Y. J. et al. High alphav integrin level of cancer cells is associated with development of brain metastasis in athymic rats. Anticancer Res. 37(8), 4029–4040 (2017).
11. Plüm, P. S. et al. HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma. BMC Cancer 19(1), 38 (2019).
12. Essakly, A. et al. PIK3CA and KRAS amplification in esophageal adenocarcinoma and their impact on the inflammatory tumor microenvironment and prognosis. Transl. Oncol. 13(2), 157–164 (2020).
13. Schroder, W. et al. Ivor-Lewis esophagectomy with and without laparoscopic conditioning of the gastric conduit. World J. Surg. 34(4), 738–743 (2010).
A.E. figure preparation, manuscript revision; A.I.D. manuscript writing, data handling; T.Z. database organization, statistical supervision; H.L. manuscript writing, pathology assessment; M.S. data acquisition, H.F. tumor operations, data acquisition; manuscript writing, statistical analysis, data management. All authors reviewed the manuscript.

14. Holscher, A. H. et al. Laparoscopic ischemic conditioning of the stomach for esophageal replacement. *Ann. Surg.* **245**(2), 241–246 (2007).
15. Messager, M. et al. Laparoscopic gastric mobilization reduces postoperative mortality after esophageal cancer surgery: a French nationwide study. *Ann. Surg.*** **262**(5), 817–822 (2015).
16. Mariette, C. et al. Hybrid minimally invasive esophagectomy for esophageal cancer. *N. Engl. J. Med.* **380**(2), 152–162 (2019).
17. Simon, R., Mirlacher, M. & Sauter, G. Tissue microarrays. *Methods Mol. Med.* **114**, 257–268 (2005).
18. Schuffnan, L. M. et al. Dickkopf-2 (DKK2) as context dependent factor in patients with esophageal adenocarcinoma. *Cancers* **12**(2), 1 (2020).
19. Schallenberg, S. et al. Loss of the SWI/SNF-ATPase subunit members SMARC1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARC8 (INI1) in esophageal adenocarcinoma. *BMC Cancer* **20**(1), 12 (2020).
20. Loeser, H. et al. The expression of the immune checkpoint regulator VISTA correlates with improved overall survival in pT1/2 tumor stages in esophageal adenocarcinoma. *Oncotarget* **8**(3), e1581164 (2019).
21. Quas, A. et al. Genomic characterization of TP53-wild-type esophageal carcinoma. *Transl. Oncol.* **12**(1), 154–161 (2019).
22. Bonnans, C., Chou, J. & Verb, Z. Remodelling the extracellular matrix in development and disease. *Nat. Rev. Mol. Cell. Biol.* **15**(12), 786–801 (2014).
23. Halmidi, H. & Ivaska, J. Every step of the way: integrins in cancer progression and metastasis. *Nat. Rev. Cancer* **18**(9), 533–548 (2018).
24. Niu, J. & Li, Z. The roles of integrin alphavbeta6 in cancer. *Cancer Lett.* **403**, 128–137 (2017).
25. Moore, K. M. et al. Therapeutic targeting of integrin alphavbeta6 in breast cancer. *J. Natl. Cancer Inst.* **106**(8), 1 (2014).
26. Stojanovic, N. et al. Differential effects of integrin alphav knockdown and cilegdtide on sensitization of triple-negative breast cancer and melanoma cells to microtubule poisons. *Mol Pharmacol.* **94**(6), 1334–1351 (2018).
27. Goldberg, L. et al. Alphav integrin expression is a novel marker of poor prognosis in advanced-stage ovarian carcinoma. *Clin. Cancer Res.* **7**(12), 4073–4079 (2001).
28. Xiong, S. et al. TGFbeta1 induces endometrial cancer cell adhesion and migration by up-regulating integrin alphavbeta3 via SMAD-independent MEK-ERK1/2 signaling. *Cell Signal* **34**, 92–101 (2017).
29. McNeill, B. et al. Collagen matrix-induced expression of integrin alphavbeta3 in circulating angiogenic cells can be targeted by matricellular protein CCN1 to enhance their function. *FASEB J.* **29**(4), 1198–1207 (2015).
30. DebreliCoskun, M. et al. alphavbeta3 integrin antagonists enhance chemotherapy response in an orthotopic pancreatic cancer model. *Front. Pharmacol.* **11**, 95 (2020).
31. Horioka, K. et al. Suppression of CD51 in pancreatic stellate cells inhibits tumor growth by reducing stroma and altering tumor-stromal interaction in pancreatic cancer. *Int. J. Oncol.* **48**(4), 1499–1508 (2016).
32. Kimura, R. H. et al. Pharmacokinetically stabilized cystine knot peptides that bind alpha-v-beta-6 integrin with single-digit nanomolar affinities for detection of pancreatic cancer. *Clin. Cancer Res.* **18**(3), 839–849 (2012).
33. Thomas, G. J. et al. Alphavbeta6 integrin promotes invasion of squamous carcinoma cells through up-regulation of matrix metalloproteinase-9. *Int. J. Cancer* **92**(5), 641–650 (2001).
34. Brown, N. F. & Marshall, J. F. Integrin-mediated TGFbeta activation modulates the tumour microenvironment. *Cancers* **11**(9), 1 (2019).
35. Feldkoren, B. et al. Integln signaling potentiates transforming growth factor-beta 1 (TGF-beta1) dependent down-regulation of E-Cadherin expression: important implications for epithelial to mesenchymal transition (EMT) in renal cell carcinoma. *Exp. Cell Res.* **355**(2), 57–66 (2017).
36. Annes, J. P. et al. Integln alphavbeta6-mediated activation of latent TGF-beta requires the latent TGF-beta binding protein-1. *J. Cell Biol.* **165**(6), 723–734 (2004).
37. Jenkins, R. G. et al. Ligation of protease-activated receptor 1 enhances alphavbeta6 integrin-dependent TGF-beta activation and promotes acute lung injury. *J. Clin. Invest.* **116**(6), 1606–1614 (2006).
38. Cooper, J. & Giancotti, F. G. Integrin signaling in cancer: mechanotransduction, stemness, epithelial plasticity, and therapeutic resistance. *Cancer Cell* **35**(3), 367–367 (2019).
39. Macias-Perez, I. et al. Loss of integrin alphavbeta1 ameliorates Kras-induced lung cancer. *Cancer Res.* **68**(15), 6127–6135 (2008).
40. Yoon, H. H. et al. Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma. *J. Clin. Oncol.* **30**(32), 3932–3938 (2012).
41. Nones, K. et al. Genomic catastrophes frequently arise in esophageal adenocarcinoma and drive tumorigenesis. *Nat. Commun.* **5**, 5224 (2014).
42. Muller, P. A. et al. Mutant p53 drives invasion by promoting integrin recycling. *Cell* **139**(7), 1327–1341 (2009).
43. Janouškova, H. et al. Activation of p53 pathway by Nutlin-3a inhibits the expression of the therapeutic target alphav5 integrin in colon cancer cells. *Cancer Lett.* **336**(2), 307–318 (2013).
44. Vranas, D. et al. ABC Transporters and Their Role in the Neoadjuvant Treatment of Esophageal Cancer. *Int. J. Mol. Sci.* **19**(3), 1 (2018).

Author contributions
H.L. manuscript writing, pathology assessment; M.S. data acquisition, H.F. tumor operations, data acquisition; A.E. figure preparation, manuscript revision; A.I.D. manuscript writing, data handling; T.Z. database organization, statistical supervision; R.B. pathology supervision, manuscript revision; W.S. tumor operation, data acquisition, manuscript revision; C.J.B. manuscript writing; A.Q. pathology assessment, data acquisition; F.G. manuscript writing, statistical analysis, data management. All authors reviewed the manuscript.

Funding
Open Access funding enabled and organized by Projekt DEAL.

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to F.G.

Reprints and permissions information
is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
